EP Patent

EP4171570A1 — Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor

Assigned to Boehringer Ingelheim International GmbH · Expires 2023-05-03 · 3y expired

What this patent protects

The invention describes anti-cancer therapies comprising using a SOS1 inhibitor in combination with a KRAS G12C inhibitor, each as described herein.

USPTO Abstract

The invention describes anti-cancer therapies comprising using a SOS1 inhibitor in combination with a KRAS G12C inhibitor, each as described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP4171570A1
Jurisdiction
EP
Classification
—
Expires
2023-05-03
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.